ライフサイエンスコーパス: polycystic ovary syndrome

1 ulation rates among infertile women with the polycystic ovary syndrome.

2 seen in diseases of excess androgens such as polycystic ovary syndrome.

3 lays a key role in the early pathogenesis of polycystic ovary syndrome.

4 ND1A) previously shown to be associated with polycystic ovary syndrome.

5 of adolescents are presenting with signs of polycystic ovary syndrome.

6 enital adrenal hyperplasia often develop the polycystic ovary syndrome.

7 narche and hyperandrogenic disorders such as polycystic ovary syndrome.

8 serum androgen concentrations in women with polycystic ovary syndrome.

9 associated with infertile conditions such as polycystic ovary syndrome.

10 ix to eight weeks in 44 obese women with the polycystic ovary syndrome.

11 ostic decisions and treating infertility and polycystic ovary syndrome.

12 daily for 35 days in 61 obese women with the polycystic ovary syndrome.

13 genaemia which is a common characteristic of polycystic ovary syndrome.

14 ur to eight weeks in 24 obese women with the polycystic ovary syndrome.

15 0c17 alpha activity are both features of the polycystic ovary syndrome.

16 Polycystic ovary syndrome, a fertility disorder affectin

17 eving live birth in infertile women with the polycystic ovary syndrome, although multiple birth is a

18 ppearing more frequently in type 2 diabetic, polycystic ovary syndrome and CHD cases.

19 veral phenotypes, including type 1 diabetes, polycystic ovary syndrome, and birth weight.

20 g obesity, type 2 diabetes, hepatitis C, and polycystic ovary syndrome, and is a primary feature of m

21 a) improves ovulatory function in women with polycystic ovary syndrome, and specific dietary fatty ac

22 Obese women with the polycystic ovary syndrome are relatively unresponsive to

23 line infertility treatment in women with the polycystic ovary syndrome, but aromatase inhibitors, inc

24 ene can be increased in obese women with the polycystic ovary syndrome by decreasing insulin secretio

25 In obese women with the polycystic ovary syndrome, decreasing serum insulin conc

26 56), after adjustment for education, parity, polycystic ovary syndrome, energy intake, and physical a

27 s for the analysis of a previously described polycystic ovary syndrome gene expression dataset.

28 MI 33 kg/m(2)), insulin-resistant women with polycystic ovary syndrome had aberrant skeletal muscle m

29 The two common forms of polycystic ovary syndrome have different origins in intr

30 Women with the polycystic ovary syndrome have insulin resistance and hy

31 of underlying androgen excess, particularly polycystic ovary syndrome in women.

32 The polycystic ovary syndrome is a common cause of infertili

33 Polycystic ovary syndrome is characterized by an excess

34 Polycystic ovary syndrome is estimated to affect 5-10% o

35 nce thought to affect primarily adult women, polycystic ovary syndrome is frequently diagnosed during

36 Polycystic ovary syndrome is the most common cause of an

37 an overview of our current understanding of polycystic ovary syndrome, its epidemiology and natural

38 the University of California, San Francisco, Polycystic Ovary Syndrome Multidisciplinary Clinic over

39 ively due to its associations with diabetes, polycystic ovary syndrome, obesity and birth size.

40 Polycystic ovary syndrome (PCOS) affects 5% of reproduct

41 tatic model assessment [HOMA]) in women with polycystic ovary syndrome (PCOS) and chronic periodontit

42 terleukin-6 (IL-6) in non-obese females with polycystic ovary syndrome (PCOS) and either clinically h

43 tor of MMP-1 (TIMP)-1 ratio in patients with polycystic ovary syndrome (PCOS) and systemically health

44 Pregnant women with polycystic ovary syndrome (PCOS) are often overweight or

45 Ms R, a 27-year-old woman with polycystic ovary syndrome (PCOS) diagnosed after irregul

46 Women with polycystic ovary syndrome (PCOS) exhibit elevated androg

47 ars, it has been clearly documented that the polycystic ovary syndrome (PCOS) has major metabolic seq

48 female first-degree relatives of women with polycystic ovary syndrome (PCOS) have hyperandrogenemia

49 Approximately 70% of women with polycystic ovary syndrome (PCOS) have intrinsic insulin

50 an morphologic measurements for diagnosis of polycystic ovary syndrome (PCOS) in adolescents.

51 Polycystic ovary syndrome (PCOS) is a common endocrine d

52 Polycystic ovary syndrome (PCOS) is a common endocrine d

53 Polycystic ovary syndrome (PCOS) is a common problem amo

54 Polycystic ovary syndrome (PCOS) is a common, highly her

55 Polycystic ovary syndrome (PCOS) is a complex hormonal d

56 Polycystic ovary syndrome (PCOS) is a leading cause of a

57 The polycystic ovary syndrome (PCOS) is an extremely common

58 Polycystic ovary syndrome (PCOS) is associated with card

59 Polycystic ovary syndrome (PCOS) is associated with insu

60 Polycystic ovary syndrome (PCOS) is associated with the

61 Use of metformin in polycystic ovary syndrome (PCOS) is becoming increasingl

62 Polycystic ovary syndrome (PCOS) is frequently associate

63 nostic criteria in women suspected of having polycystic ovary syndrome (PCOS) is incomplete.

64 Polycystic ovary syndrome (PCOS) is the most common repr

65 ly, some studies have revealed the effect of polycystic ovary syndrome (PCOS) on gingival inflammatio

66 Polycystic ovary syndrome (PCOS) recently has been ident

67 Insulin resistance in polycystic ovary syndrome (PCOS) results from a postbind

68 hyperandrogenic insulin-resistant women with polycystic ovary syndrome (PCOS) who are at increased ri

69 d androgen excess with insulin resistance in polycystic ovary syndrome (PCOS) women.

70 Using an ovine model of polycystic ovary syndrome (PCOS), (pregnant ewes injecte

71 Maternal polycystic ovary syndrome (PCOS), a common metabolic dis

72 This would suggest that maternal polycystic ovary syndrome (PCOS), a condition associated

73 n to this model because it is usually due to polycystic ovary syndrome (PCOS), a condition in which i

74 nd stroma are also prominent features of the polycystic ovary syndrome (PCOS), a leading cause of inf

75 Endothelin-1 is elevated in women with polycystic ovary syndrome (PCOS), and may play a role in

76 alleles are associated with type 2 diabetes, polycystic ovary syndrome (PCOS), and size at birth.

77 Dyslipidemia is a feature of polycystic ovary syndrome (PCOS), but its pathogenesis r

78 Polycystic ovary syndrome (PCOS), characterized by incre

79 ty, and hirsutism, common characteristics of polycystic ovary syndrome (PCOS), improve with even mode

80 oxidative stress, in the pathophysiology of polycystic ovary syndrome (PCOS), the most common endocr

81 levels correlate with increased severity of polycystic ovary syndrome (PCOS).

82 ciated with insulin resistance in women with polycystic ovary syndrome (PCOS).

83 yperandrogenism are the cardinal features of polycystic ovary syndrome (PCOS).

84 s increasing evidence of their importance in polycystic ovary syndrome (PCOS).

85 fertility and thus serve as a model of human polycystic ovary syndrome (PCOS).

86 has metabolic advantages in the treatment of polycystic ovary syndrome (PCOS).

87 to the concentrations that can occur during polycystic ovary syndrome (PCOS).

88 thesis and/or metabolism in the aetiology of polycystic ovary syndrome (PCOS).

89 An association between polycystic ovary syndrome (PCOS)and endometrial carcinom

90 d androgen excess and a phenotype resembling polycystic ovary syndrome (PCOS; refs. 1,2).

91 eted educational qualification, nulliparity, polycystic ovary syndrome, physical activity, and body m

92 rched PubMed using a string of variations of polycystic ovary syndrome, therapy/treatment, and adoles

93 s the action of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory f

94 ndomly assigned 626 infertile women with the polycystic ovary syndrome to receive clomiphene citrate

95 nificant benefit when including metformin in polycystic ovary syndrome treatment regimens.

96 evels, that they hypothesized could point to polycystic ovary syndrome underpinning these association

97 The polycystic ovary syndrome was defined according to modif

98 ulin resistance is observed in patients with polycystic ovary syndrome, we hypothesized that TAC or S

99 proate, is associated with the occurrence of polycystic ovary syndrome when used in young adulthood o

100 ons, linking dementia with bone development, polycystic ovary syndrome with cardiovascular developmen